Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 29, 2017
Pharmacy Choice - News - Front Page Healthcare News - March 29, 2017

Pharmacy News

 Front Page Healthcare News
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

3/29/17 - AP Top Health News at 8:05 p.m. EDT
Brain and arm implants help paralyzed US man feed himself ACLU asks Ohio city to stop charging drug overdose survivors Senate, White House pass on House push to revive health bill Democratic senator asks drugmakers about opioid sales plans States push to protect birth control despite failed GOP bill FDA approves 1st drug for moderate& severe eczema
3/29/17 - AP Top Health News at 8:16 p.m. EDT
Brain and arm implants help paralyzed US man feed himself ACLU asks Ohio city to stop charging drug overdose survivors Senate, White House pass on House push to revive health bill Democratic senator asks drugmakers about opioid sales plans States push to protect birth control despite failed GOP bill FDA approves 1st drug for moderate& severe eczema
3/29/17 - British new lung cancer drug wins approval in China [Philippines News Agency]
The London stock market listed company AstraZeneca Monday announced that the China Food and Drug Administration has granted marketing authorization for its lung cancer pill Tagrisso in China. Tagrisso is designed for the treatment of adult patients with certain genetic mutations, which is the first AstraZeneca medicine approved under the CFDA's...
3/29/17 - Center Point Clinical Services' Studies Show That Pharmacist-led Interventions Increase Clinical Trial Patient Medication Adherence and Compliance and Provide Robust Study Data
Center Point Clinical Services, creator of the world's first Siteless CRO platform, announced today study results presented in two separate posters at the Academy of Managed Care Pharmacy,# AMCP2017, Managed Care and Specialty Pharmacy annual meeting in Denver, Colorado. Joe Martinez, CEO of Center Point Clinical Services and the lead author of bot
3/29/17 - EDITORIAL: Health care battle lives on [Waterloo-Cedar Falls Courier, Iowa]
March 28 Democrats may rejoice about the Republican Party's civil war that doomed its ill-conceived attempt to "repeal and replace" the Affordable Care Act, but the battle over the national health care program isn't over. "We're going to be living with' Obamacare' for the foreseeable future," said House Speaker Paul Ryan, R- Wis., after pulling
3/29/17 - Enrollment Commences in Phase III Clinical Study of Eisai's Bace Inhibitor Elenbecestat in Early Alzheimer's Disease in Japan
TOKYO, Mar 29, 2017 Eisai Co., Ltd. announced today that enrollment has commenced in Japan for MISSION AD1, a global Phase III clinical study of the in-house developed oral beta secretase cleaving enzyme inhibitor elenbecestat in patients with early Alzheimer's disease. The Phase III clinical trial program for elenbecestat consists of two global
3/29/17 - FDA Approves Genentech's OCREVUS? (Ocrelizumab) for Relapsing and Primary Progressive Forms of Multiple Sclerosis
Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration approved OCREVUS? as the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis. The FDA s approval of OCREVUS is the beginning of a new era for the MS community and represents a significant scientific a
3/29/17 - North American Health Headlines at 8:05 p.m. EDT
Senate, White House pass on House push to revive health bill States push to protect birth control despite failed GOP bill Democratic senator asks drugmakers about opioid sales plans Trumps says he expects a health care deal soon FDA approves 1st drug for moderate& severe eczema cases
3/29/17 - North American Health Headlines at 8:16 p.m. EDT
Senate, White House pass on House push to revive health bill States push to protect birth control despite failed GOP bill Democratic senator asks drugmakers about opioid sales plans Trump says he expects a health care deal soon FDA approves 1st drug for moderate& severe eczema cases
3/29/17 - Purdue Pharma Highlights Research from Multiple Studies at AMCP Managed Care & Specialty Pharma Annual Meeting 2017
Purdue Pharma L.P. announced today the presentation of results from six clinical and non-clinical research studies at the Academy of Managed Care Pharmacy Managed Care& Specialty Pharmacy Annual Meeting 2017 in Denver, Mar. 27-30, 2017. We are pleased to present results from several studies that show our commitment to the pain community while ad
3/29/17 - Regeneron Says FDA Okays New Eczema Drug Dupixent
PARIS- Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration approved DUPIXENT or dupilumab Injection, the first and only biologic medicine approved for the treatment of adults with moderate-to-severe atopic dermatitis or AD whose disease is not adequately controlled with topical prescription therapies, or.
3/28/17 - "Method of Making a Prosthetic Valve and Valve Obtained Therewith" in Patent Application Approval Process (USPTO 20170065408)
By a News Reporter-Staff News Editor at Life Science Weekly A patent application by the inventors GRUNDEMAN, Paul Frederik; KLUIN, Jolanda; BOON-CEELEN, Karlien Kristel; KONIG, Thomas, filed on May 6, 2015, was made available online on March 16, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This pa
3/28/17 - 2017 France Microbiology Automated Market: Supplier Shares and Strategies, Country Segment Forecasts, Technology Trends, Instrumentation ReviewMolecular Diagnostics, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screenin
Complete report $6,950. DataPack $4,500. VPGMarketResearch.com' s new report is an analysis of major business opportunities emerging in the French automated microbiology market during the next five years. The report examines key trends, reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies;...
3/28/17 - 4 ACA change paths that just got more popular [LifeHealthPro]
Seema Verma, the new head of CMS, owned a company that trained Indiana's HealthCare. gov navigators. Tom Bulleit, a Washington- based partner at Ropes& Gray LLP, says in a written commentary about the cancellation of the AHCA bill vote that one obvious outcome could big a bigger role for the U.S. Department of Health and Human Services, and the new
3/28/17 - AbbVie and M2Gen Announce New Collaboration for the Oncology Research Information Exchange Network (ORIEN) Avatar Research Program
NORTH CHICAGO, Ill. and TAMPA, Fla., March 28, 2017/ PRNewswire/ AbbVie, a global biopharmaceutical company, and M2Gen, a leading health informatics solutions company, announced today that AbbVie has joined the Oncology Research Information Exchange Network Avatar Research Program. ORIEN Avatar is a collaboration between the 15 leading U.S. ca
3/28/17 - AbbVie Granted Priority Review in Japan for its Investigational Regimen of Glecaprevir/Pibrentasvir G/P for the Treatment of All Major Genotypes of...
By a News Reporter-Staff News Editor at China Weekly News- AbbVie, a global biopharmaceutical company, announced that priority review has been granted by the Japanese Ministry of Health, Labour and Welfare for its investigational, pan-genotypic, ribavirin-free regimen of glecaprevir/pibrentasvir for the treatment of all major genotypes of the chr
3/28/17 - ACA repeal would have dire effects
Repealing the Affordable Care Act will have wide-ranging and destructive consequences, according to a recent Congressional Budget Office report. After Medicaid expansion, the individual mandate, and subsidies are eliminated, an additional 32 million would be uninsured by 2026; premiums would rise and double by 2026, above what they would be under t
3/28/17 - ACETO Subsidiary, Rising Pharmaceuticals, Launches Capecitabine Tablets, 150 & 500 mg
ACETO Corporation, an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals, its finished dosage form generics subsidiary, has launched Capecitabine Tablets, 150& 500 mg, an AB-rated generic vers
3/28/17 - Adamas Announces Data Presentation on ADS-5102 at the Academy of Managed Care Pharmacy 2017 Annual Meeting
Adamas Pharmaceuticals, Inc. today announced details regarding a poster presentation highlighting data from EASE LID, its Phase 3 efficacy study of ADS-5102 extended-release capsules for the treatment of levodopa-induced dyskinesia in patients with Parkinson s disease, to be presented at the Academy of Managed Care Pharmacy s 2017 Annual Me
3/28/17 - Adamas to Present at the 16th Annual Needham Healthcare Conference
Adamas Pharmaceuticals, Inc. today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, is scheduled to present at the Needham Healthcare Conference in New York on Tuesday, April 4, 2017 at 10:40 a.m. Eastern Time.. An NDA supporting ADS-5102 for the treatment of LID in patients with Parkinson s disease is und
3/28/17 - Aerie Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference
Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present at the 16th Annual Needham Health
3/28/17 - Akebia Announces Publication of Phase 2a Results for Vadadustat in Patients with Anemia Related to Chronic Kidney Disease
Akebia Therapeutics, Inc., a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor, today announced the publication of positive results from a Phase 2 a study of vadadustat, a once-daily oral HIF stabilizer in development for the treatment of anemia relat
3/28/17 - Allergan, Paratek Announce Positive Results from Two Phase 3 Trials for Moderate-to-Severe Acne Treatment [T-break Tech (Middle East)]
Allergan, a leading global pharmaceutical company and Paratek Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, announced that two Phase 3 trials of sarecycline for the treatment of moderate to severe acne met their 12 week primary efficacy...
3/28/17 - Alnylam to Webcast Presentation at 16th Annual Needham Healthcare Conference
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that management will present a company overview at the 16 th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at 11:20 am ET at the Westin Grand Central Hotel in New York City. About Alnylam Pharmaceuticals Alnylam is a biopharmaceutical company...
3/28/17 - American Health Council Names Mrs. Rachel Askew, MSN, BSN, RN to Nursing Board
Mrs. Rachel Askew, Manager of High Risk Care Management - Population Health at Lake Health Hospital System, has been selected to join the Nursing Board at the American Health Council.
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415